Duobrii (halobetasol propionate and tazarotene)

pCPA File Number: 21312

Negotiation Status:

Concluded with an LOI

Indication(s):

Psoriasis, moderate to severe plaque

Sponsor/Manufacturer:

Bausch Health, Canada Inc.

CDA-AMC Project Number:

SR0638-000

pCPA Engagement Letter Issued:

2021-09-17

Negotiation Process Concluded:

2021-11-30